Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients

Human studies on the effect of rosiglitazone on inflammatory bowel disease (IBD) are still lacking. We investigated whether rosiglitazone might affect IBD risk by using the reimbursement database of Taiwan’s National Health Insurance to enroll a propensity-score-matched cohort of ever users and neve...

Descripción completa

Detalles Bibliográficos
Autor principal: Tseng, Chin-Hsiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223056/
https://www.ncbi.nlm.nih.gov/pubmed/37242462
http://dx.doi.org/10.3390/ph16050679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223056/
https://www.ncbi.nlm.nih.gov/pubmed/37242462
http://dx.doi.org/10.3390/ph16050679

Ejemplares similares